

Papua New Guinea

Population 2015

7.6 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	3.1 (1.8–4.6)	40 (24–61)
Mortality (HIV+TB only)	0.67 (0.4–1)	8.8 (5.2–13)
Incidence (includes HIV+TB)	33 (27–40)	432 (352–521)
Incidence (HIV+TB only)	4.9 (3–7.3)	64 (39–96)
Incidence (MDR/RR-TB)**	1.9 (1.2–2.5)	25 (16–33)

Estimated TB incidence by age and sex (thousands)*, 2015

	0-14 years	> 14 years	Total
Females	2 (1.1–2.9)	14 (11–18)	16 (12–21)
Males	1.6 (0.99–2.2)	15 (12–19)	17 (13–21)
Total	3.6 (2.4–4.8)	29 (26–33)	33 (27–40)

TB case notifications, 2015

Total cases notified	28 696
Total new and relapse	26 347
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	36%
- % pulmonary	54%
- % bacteriologically confirmed among pulmonary	31%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	80% (66–98)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.11 (0.07–0.17)

TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	758	8%
- on antiretroviral therapy	494	65%

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			1 100 (800–1 500)
Estimated % of TB cases with MDR/RR-TB	3.4% (1.7–5)	26% (15–36)	
% notified tested for rifampicin resistance			1 895
MDR/RR-TB cases tested for resistance to second-line drugs			147
Laboratory-confirmed cases		MDR/RR-TB: 254, XDR-TB: 11	
Patients started on treatment ****		MDR/RR-TB: 225, XDR-TB: 11	

Treatment success rate and cohort size

	Success	Cohort
New cases registered in 2014	70%	4 077
Previously treated cases registered in 2014	63%	728
HIV-positive TB cases, all types, registered in 2014		
MDR/RR-TB cases started on second-line treatment in 2013		
XDR-TB cases started on second-line treatment in 2013		

TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016

National TB budget (US\$ millions)	11
Funding source: domestic, 100% international, 0% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015




Treatment success rate (%)



— New cases
— Previously treated cases
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



— Unfunded
— Funded internationally
— Funded domestically